|N/A – drug metabolite|
|Chemical and physical data|
|Molar mass||255.741 g/mol g·mol−1|
|3D model (JSmol)|
Hydroxybupropion (code name BW 306U), or 6-hydroxybupropion, is the major active metabolite of the antidepressant and smoking cessation drug bupropion. It is formed from bupropion by the liver enzyme CYP2B6 during first-pass metabolism. With oral bupropion treatment, hydroxybupropion is present in plasma at area under the curve concentrations that are as many as 16–20 times greater than those of bupropion itself, demonstrating extensive conversion of bupropion into hydroxybupropion in humans. As such, hydroxybupropion is likely to play a very important role in the effects of oral bupropion, which could accurately be thought of as functioning largely as a prodrug to hydroxybupropion.
Compared to bupropion, hydroxybupropion is similar in its potency as a norepinephrine reuptake inhibitor (IC50 = 1.7 µM) (and likely also acts as a norepinephrine releasing agent, similarly to bupropion), but is substantially weaker as a dopamine reuptake inhibitor (IC50 = >10 µM). Like bupropion, hydroxybupropion is also a non-competitive antagonist of nACh receptors, such as α4β2 and α3β4, but is even more potent in comparison.
Bupropion is extensively and rapidly absorbed in the gastrointestinal tract but experiences extensive first pass metabolism rendering its systemic bioavailability limited. Exact bioavailability has yet to be determined given an intravenous form does not exist. Absorption is suggested to be between 80-90%. Its distribution half-life is between 3–4 hours and exhibits moderate human plasma protein binding (between 82-88%) with the parent compound and hydroxybupropion displaying the highest affinity. Bupropion is a racemic mixture and is metabolized hepatically primarily via oxidative cleavage of its side chains by CYP2B6. Hydroxybupropion is the most potent of the metabolites. It is formed via the “hydroxylation of the tert-butyl group” by CYP2B6 and is excreted renally. Cmax vales of hydroxybupropion are 4-7 times that of bupropion, while the exposure to hydroxybupropion is "10 fold" that of bupropion. Hydroxybupropion's elimination half-life is roughly 20 hours, give or take 5 hours and will reach steady state concentrations within 8 days.
Although there are patents proposing uses and formulations of this compound, hydroxybuproprion is not currently marketed as a drug in and of itself and is only available for use in non-clinical research. Hydroxybupropion is not a scheduled drug or a controlled substance. One can access GLP (Good Lab Practice) documents detailing assays/techniques to further research and isolate this drug. Otherwise, there is little regulatory data available for hydroxybupropion at this time. Moreover, there is little information to suggest hydroxybupropion has an abuse potential. However, it has been studied as a possible therapeutic for alcohol and nicotine abuse as a codrug.
There are few clinical trials or toxicology studies assessing hydroxybupropion alone at this time. There are clinical studies which assess hydroxybupropion in conjunction with bupropion suggesting hydroxybupropion to be the primary form of the compound responsible for its clinical efficacy. Also, transdermal delivery of bupropion and hydroxybupropion has been assessed finding bupropion to be the superior candidate given its elevated diffusion rate through skin samples. There are few toxicology studies assessing hydroxybupropion alone at this time. However, there are some studies which assess this compound in conjunction with others or its parent compound.
- Radafaxine – the (2S,3S)- isomer of hydroxybupropion
- Manifaxine – an analogue of radafaxine and hydroxybupropion
- Linda P. Dwoskin (29 January 2014). Emerging Targets & Therapeutics in the Treatment of Psychostimulant Abuse. Elsevier Science. pp. 177–216. ISBN 978-0-12-420177-4.
- Thomas L. Lemke; David A. Williams (24 January 2012). Foye's Principles of Medicinal Chemistry. Lippincott Williams & Wilkins. pp. 612–. ISBN 978-1-60913-345-0.
- Damaj MI, Carroll FI, Eaton JB, et al. (September 2004). "Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors". Mol. Pharmacol. 66 (3): 675–82. doi:10.1124/mol.104.001313. PMID 15322260.
- Zhu AZ, Cox LS, Nollen N, et al. (December 2012). "CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion". Clin. Pharmacol. Ther. 92 (6): 771–7. doi:10.1038/clpt.2012.186. PMC 3729209. PMID 23149928.
- Lewis E. Foxhall; Maria Alma Rodriguez (11 October 2014). Advances in Cancer Survivorship Management. Springer. pp. 265–. ISBN 978-1-4939-0986-5.
- Bankole A. Johnson (10 October 2010). Addiction Medicine: Science and Practice. Springer Science & Business Media. pp. 433–. ISBN 978-1-4419-0338-9.
- Dhillon S.; Yang L. P. H.; Curran M. P. (2008). "A Review of its Use in the Management of Major Depressive Disorder". Drugs. 68 (5): 653–689. doi:10.2165/00003495-200868050-00011. PMID 18370448.
- National Center for Biotechnology Information. (n.d.).PubChem Open Database. Buproprion, CID 62889. Retrieved from https://pubchem.ncbi.nlm.nih.gov/compound/62884?from=summary - x291#section=Top.
- Glaxosmithkline. (2004). (bupropion hydrochloride) Tablets. Retrieved from http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4065b1-20-tab11A-Wellbutrin-Tabs-SLR028.pdf
- Jefferson, JW; Pradko, JF; Muir, KT (November 2005). "Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations". Clinical Therapeutics. 27 (11): 1685–95. doi:10.1016/j.clinthera.2005.11.011. PMID 16368442.
- orangebook, http://www.deadiversion.usdoj.gov/schedules/orangebook/orangebook.pdf
- VALIDATED ASSAYS FOR HUMAN CYTOCHROME P450 ACTIVITIES, http://dmd.aspetjournals.org/content/32/6/647.full.pdf+html
- Coles, R.; Kharasch, E. (2007-09-15). "Stereoselective analysis of bupropion and hydroxybupropion in human plasma and urine by LC/MS/MS". Journal of Chromatography B. 857 (1): 67–75. doi:10.1016/j.jchromb.2007.07.007. PMID 17656162.
- Hamad MO, Kiptoo PK, Stinchcomb AL, Crooks PA (2006-10-15). "Synthesis and hydrolytic behavior of two novel tripartite codrugs of naltrexone and 6β-naltrexol with hydroxybupropion as potential alcohol abuse and smoking cessation agents". Bioorganic & Medicinal Chemistry. 14 (20): 7051–7061. doi:10.1016/j.bmc.2006.06.018. PMID 16798000.
- Carroll FI, Blough BE, Mascarella SW, Navarro HA, Lukas RJ, Damaj MI (2014). Bupropion and Bupropion Analogs as Treatments for CNS Disorders. Advances in Pharmacology. 69. pp. 177–216. doi:10.1016/B978-0-12-420118-7.00005-6. ISBN 9780124201187. PMID 24484978.
- Zhu AZ, Cox LS, Nollen N, Faseru B, Okuyemi KS, Ahluwalia JS, Benowitz NL, Tyndale RF (Dec 2012). "CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion". Clin Pharmacol Ther. 92 (6): 771–7. doi:10.1038/clpt.2012.186. PMC 3729209. PMID 23149928.
- Kiptoo PK, Paudel KS, Hammell DC, Pinninti RR, Chen J, Crooks PA, Stinchcomb AL (Feb 2009). "Transdermal delivery of bupropion and its active metabolite, hydroxybupropion: a prodrug strategy as an alternative approach". J Pharm Sci. 98 (2): 583–94. doi:10.1002/jps.21463. PMC 2612091. PMID 18623203.